对气道重塑的潜在影响:虽然目前尚无专门针对 TSLP 抑制对气道重塑影响机制的研究,但 PATHWAY 和 NAVIGATOR 试验的数据提供了一些见解。PATHWAY 试验的事后分析显示,tezepelumab 降低了基质重塑蛋白(如基质金属蛋白酶 - 10(MMP - 10)和 pe...
图1 胸腺基质淋巴细胞生成素(TSLP)在皮肤病中的作用机制TSLP通过STAT及NF-κB途径促进树突细胞分化并产生Th2细胞因子,导致机体Th1/Th2免疫失衡,从而诱发多种皮肤疾病。TSLPR:TSLP受体;JAK:酪氨酸激酶蛋白;STAT:信号转导与转录活化因子;CCL17:...
View Larger ImageTSLP Mediates Cross Talk Between Cancer Cells and the Immune System.Tumor cells or cancer-associated fibroblasts produce TSLP that promotes immature DC (iDC) maturation and production of CCL17, CCL22, and OX40 Ligand by monocyte-derived dendritic cells (MoDCs). The chemokines att...
IL-4是2型淋巴细胞分化的中心介质；它诱导产生2型相关细胞因子，如IL-5、IL-9、IL-13和/或2型相关趋化因子，如胸腺和活化调节趋化因子(TARC/CCL17)和嗜酸性粒细胞趋化因子-3。IL-4参与调节B细胞的同种型类别转换以产生血清IgE，并通过释放IL-5招募嗜酸性粒细胞。尽管IL-13在这些促炎过程中显示出一些冗余性...
TSLP与树突细胞上的TSLPR结合,会引起树突细胞的活化,树突细胞活化表现出趋化因子(如TARC,又名CCL17)的分泌。通过检测TARC可有效评价重组抗TSLP抗体对TSLP的抑制作用。用含有10%(灭活)血清的R1640培养基重悬PBMC至2×10 7 个/mL,加入到96孔平底细胞培养板(50μL/孔)。重组抗人TSLP单克隆抗体S17C7+L3E8-M1以...
(TSLP). Human TSLPR is expressed by monocytes and CD11c+ dendritic cells, and TSLP binding induces the expression of the Th2 cell-attracting chemokines CCL17 and CCL22. Furthermore, the TSLPR-induced activation of dendritic cells indirectly results in the increased secretion ...
TSLP与树突细胞上的TSLPR结合,会引起树突细胞的活化,树突细胞活化表现出趋化因子(如TARC,又名CCL17)的分泌。通过检测TARC可有效评价重组抗TSLP抗体对TSLP的抑制作用。用含有10%(灭活)血清的R1640培养基重悬PBMC至2.5×10 6 个/mL,加入到96孔平底细胞培养板(50μL/孔)。重组抗TSLP单克隆抗体(S2B1、S2A10、S2...
Human TSLPR is expressed by monocytes and CD11c+ dendritic cells, and TSLP binding induces the expression of the Th2 cell-attracting chemokines CCL17 and CCL22. Furthermore, the TSLPR-induced activation of dendritic cells indirectly results in the increased secretion of Th cytokines IL...
We show here that human thymic stromal lymphopoietin (TSLP) potently activated CDIIc[sup +] dendritic cells (DCs) and induced production of the T[sub H]2-attracting chemokines TARC (thymus and activation-regulated chemokine; also known as CCL17) and MDC (macrophage-derived chemokine; CCL22)....
本发明的抗体分子及其抗原结合片段能够以高亲和力结合人TSLP,阻断TSLP与其受体之间的相互作用,且显著抑制树突状细胞分泌CCL17、OPG等趋化因子,可用于治疗与TSLP信号传递和/或TSLP细胞表达有关的疾病和病症,例如炎性疾病或肿瘤。 法律状态 法律状态公告日 法律状态信息 法律状态 2023-03-24 实质审查的生效IPC(主分类):...